Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 19/20 | 0.64 |
| ▸ | HTR2A | P28223 | 5/20 | 0.62 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353823 | 0.91 | CCR3 (0.76) | CCR3HTR2A | |
| SCHEMBL6841243 | 0.91 | CCR3 (0.76) | CCR3HTR2A | |
| SCHEMBL5348263 | 0.89 | CCR3 (0.69) | CCR3HTR2ACCR2 | |
| SCHEMBL5359046 | 0.88 | CCR3 (0.68) | CCR3HTR2A | |
| SCHEMBL5350885 | 0.86 | CCR3 (0.69) | CCR3HTR2ACCR2 | |
| SCHEMBL7825964 | 0.82 | CCR3 (0.75) | CCR3HTR2ACCR2 | |
| SCHEMBL7829378 | 0.80 | CCR3 (0.75) | CCR3HTR2A | |
| SCHEMBL7829233 | 0.80 | CCR3 (0.73) | CCR3HTR2ACCR2 | |
| SCHEMBL5347845 | 0.79 | CCR3 (0.81) | CCR3HTR2A | |
| SCHEMBL5351562 | 0.78 | CCR3 (0.78) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | claimed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | claimed |
| US-6759411-B2 | ANTIHISTAMINES, ANTIALLERGENS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | claimed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | claimed |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | disclosed |
| US-7312222-B2 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | disclosed |
| US-6759411-B2 | ANTIHISTAMINES, ANTIALLERGENS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | disclosed |
| US-6331545-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | CCR3 1/4885HTR2A 2011/4885CCR2 6/4885 |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | CCR3 1/4885HTR2A 2011/4885CCR2 6/4885 |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR3, CCR1, CCR4 | CCR3 1/4885HTR2A 2077/4885CCR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.